BeiGene’s billions to support new launches, deep pipeline

By enriching its coffers with a further $2.1 billion from existing shareholders, BeiGene gains a formidable cash position as it brings to market a handful of products in the U.S. and China and advances a deep oncology pipeline -- including several programs highlighted in an investor presentation last week.

The biotech named Amgen Inc. (NASDAQ:AMGN), Baker Bros. Advisors and Hillhouse Capital as investors in the registered direct offering announced Sunday. BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) did not use underwriters or placement agents; it said Credit Suisse acted as a corporate finance adviser to the board’s pricing committee...